• Press Release🔍
• phase III trials demonstrate nemolizumab's efficacy and rapid onset ...🔍
• SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis 🔍
• Phase 3 Data Analysis Presented at EADV 2023 Showed ...🔍
• Statistical Analysis Plan Study M16|047 A Phase 3 Randomized ...🔍
• Apellis Reports Positive Top|line Results from Phase 3 Head|to ...🔍
• Pfizer Announces Positive Top|Line Results from Third Phase 3 Trial ...🔍
• Incyte Presents New Late|Breaking Data from Phase 2 Study ...🔍

Press Release: Late-breaking amlitelimab Phase 2b data presented ...

29.4% at week 16 and 27.6% at week 24 for placebo. Professor Stephan ... Phase 2 clinical development, and 1 in Phase 3 clinical development.

phase III trials demonstrate nemolizumab's efficacy and rapid onset ...

... weeks thereafter. Clinical non-responder patients at week 16 could enroll into a long-term extension study. About the OLYMPIA 1 trial.

SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps)

MAINTENANCE OF RESPONSE1: 88% of PASI 90 responders at Week 16 maintained response at Week 52. ... In the second phase of this study (Week 28 through Week ...

Phase 3 Data Analysis Presented at EADV 2023 Showed ...

In these studies, bimekizumab demonstrated clinical meaningful improvements for these outcomes over placebo at Week 16, with improvements ...

Statistical Analysis Plan Study M16-047 A Phase 3 Randomized ...

response after Week 16 until Week 52, by visit and overall; loss of response is ... the maximum placebo rate in upadacitinib AD Phase 2b study and ...

Apellis Reports Positive Top-line Results from Phase 3 Head-to ...

... week 16 (p<0.0001). At week 16, pegcetacoplan-treated patients (n=41) had an adjusted mean hemoglobin increase of 2.4 g/dL from a baseline ...

Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial ...

Abrocitinib (100mg) with dupilumab matching placebo administered by subcutaneous injection every other week from Day 1 to Week 16, followed by ...

Incyte Presents New Late-Breaking Data from Phase 2 Study ...

Randomized Phase 2 study met its primary and secondary endpoints following 16 weeks of treatment across all dosing groups, ...

A Comprehensive Review of Biologics in Phase III and IV Clinical ...

Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis ...

Safety and efficacy of mirikizumab versus secukinumab and placebo ...

... phase 3, multicentre, randomised, double-blind study. Author links open ... week 16 to 32 and then every 8 weeks from week 32 to 52. The primary outcome ...

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK ...

Comparators will include placebo, through Week 16, and apremilast, a widely used oral drug for the treatment of psoriasis, through Week 24. Each ...

Phase 3 Data for Bimekizumab Shows Well Maintained Response

The studies enrolled 1,014 patients (n=505 in BE HEARD I; n=509 in BE HEARD II) for 16-week initial and 32-week maintenance treatment periods ...

Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable ...

Patients had baseline Pruritus NRS ≥ 3 and achieved a ≥ 3-point improvement at Week 16. ... week randomized controlled phase 3 trial. J Am ...

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating

Comparators will include placebo, through Week 16, and apremilast, a widely used oral drug for the treatment of psoriasis, through Week 24. Each ...

New Phase 3 Data Suggest Long-Term Efficacy of Upadacitinib in ...

... week 16. Patients, aged 12 to 75, with moderate to severe AD were randomized into three groups: UPA 15 mg (UPA15), UPA 30 mg (UPA30), or ...

Kyowa Kirin Announces Top-line Data from Rocatinlimab Phase 3 ...

... weeks for 24 weeks with a loading dose at week two. 2 Key endpoints were assessed at week 16 and week 24. Co-primary endpoints for the trial ...

338 Laboratory safety from a 16-week phase 3 study of dupilumab in ...

Neither event was associated with clinical symptoms nor led to the discontinuation of the study treatment. No clinically meaningful changes in ...

Upadacitinib in Adolescents With Moderate to Severe Atopic ...

... 3 Phase 3 Randomized Clinical Trials Through 76 Weeks. Amy S ... week 16 through week 76 for all 3 studies. These efficacy parameters ...

Results From Two Phase 3 Trials of Bimekizumab Unveiled

... week 4, then every 12 weeks), or placebo (Q4W through week 16 then bimekizumab 320 mg Q4W). Coprimary endpoints were a Psoriasis Area and ...

Bimekizumab Maintained Efficacy Responses Through 52 Weeks in ...

... Week 16: Results from a Phase 3, Randomized Study. William R Tillett1, Joseph Merola2, Yoshiya Tanaka3, Ennio G Favalli4, Dennis McGonagle5, Diamant Thaçi6 ...